You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PD1

Showing 626 - 650 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Pancreatic Cancer Trial in Hangzhou (Anti-PD-1 mAb)

Recruiting
  • Pancreatic Cancer
  • Anti-PD-1 monoclonal antibody
  • Hangzhou, Zhejiang, China
    the First Affiliated Hospital, School of Medicine, Zhejiang Univ
Jul 18, 2021

Brain Cancer Trial in United States (MK-3475)

Completed
  • Brain Cancer
  • Los Angeles, California
  • +6 more
Jun 6, 2022

Stage IV Gastric Cancer With Metastasis Trial (Camrelizumab; Nab-paclitaxel; S-1)

Not yet recruiting
  • Stage IV Gastric Cancer With Metastasis
  • Camrelizumab; Nab-paclitaxel; S-1
  • (no location specified)
Jul 5, 2022

Tumors Trial in United States (Niraparib, Pembrolizumab, TSR-042 (Dostarlimab))

Completed
Has Results
  • Neoplasms
  • Whittier, Alaska
  • +15 more
Aug 29, 2022

Glioblastoma Trial in New Haven (AB122, AB154, Placebo)

Recruiting
  • Glioblastoma
  • New Haven, Connecticut
    Yale University
Jul 5, 2022

Programmed Death Ligand-1 in Nasopharyngeal and Hyypopharyngeal

Not yet recruiting
  • Nasopharyngeal and Hypopharyngeal Carcinoma
  • immunohistochemical
  • Sohag, Egypt
    Sohag University Hospital
Oct 23, 2022

Immunotherapy, Second-line Treatment Trial in Guizhou (Cadonilimab)

Recruiting
  • Immunotherapy
  • Second-line Treatment
  • Guizhou, ZunYi, China
    The Second Affiliated Hospital of Zunyi Medical University
Jun 14, 2023

HNSCC, Melanoma, Gynecologic Cancer Trial in Portland (DP CD8 TIL, DP CD8 TIL KD, Low dose IL-2)

Recruiting
  • HNSCC
  • +5 more
  • DP CD8 TIL
  • +2 more
  • Portland, Oregon
    Providence Portland Medical Center
Jun 5, 2023

Non-clear Renal Cell Carcinoma Trial in Nanjing, Nanning (Toripalimab, Axitinib)

Recruiting
  • Non-clear Renal Cell Carcinoma
  • Nanjing, Jiangsu, China
  • +1 more
Mar 13, 2023

HNSCC Trial in Cincinnati, Cleveland, Philadelphia (Cesium-131, Pembrolizumab)

Recruiting
  • HNSCC
  • Cincinnati, Ohio
  • +2 more
Oct 4, 2022

Recurrent Glioblastoma Trial in Shanghai (Camrelizumab plus GSC-DCV, Camrelizumab plus Placebo)

Recruiting
  • Recurrent Glioblastoma
  • Camrelizumab plus GSC-DCV
  • Camrelizumab plus Placebo
  • Shanghai, Shanghai, China
    Huashan Hospital, Fudan University
Nov 28, 2021

Non Small Cell Lung Cancer Trial in Palo Alto, Sacramento, Stony Brook ([18F]F AraG)

Recruiting
  • Non Small Cell Lung Cancer
  • [18F]F AraG
  • Palo Alto, California
  • +2 more
Apr 11, 2022

Relapsed/ Refractory Multiple Myeloma Trial in Worldwide (Talquetamab, Teclistamab, PD-1 Inhibitor)

Recruiting
  • Relapsed/ Refractory Multiple Myeloma
  • Denver, Colorado
  • +19 more
Jan 27, 2023

Urothelial Cancer, Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter Trial in

Recruiting
  • Urothelial Cancer
  • +3 more
  • Sacituzumab Govitecan (SG)
  • Enfortumab vedotin-ejfv (EV)
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Sep 28, 2022

Squamous Cell Carcinoma of the Head and Neck, Melanoma, Non Small Cell Lung Cancer Trial in Worldwide (SL-279252)

Recruiting
  • Squamous Cell Carcinoma of the Head and Neck
  • +12 more
  • Nashville, Tennessee
  • +4 more
Feb 3, 2022

Locally Advanced Gastric Adenocarcinoma Trial in Tianjin (PD-1 antibody combined with FOLFIRINOX regimen, PD-1 antibody combined

Recruiting
  • Locally Advanced Gastric Adenocarcinoma
  • PD-1 antibody combined with FOLFIRINOX regimen
  • PD-1 antibody combined with SOX program
  • Tianjin, Tianjin, China
    RuiLiu
May 27, 2021

NSCLC, NSCLC, PD-1 Trial in Beijing (F520, Pemetrexed, Carboplatin)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • +2 more
  • Beijing, China
    Cancer Hospital, Chinese Academy of Medical Sciences
Feb 22, 2023

Neoadjuvant Chemotherapy and Immunotherapy for HER2(-),pMMR

Recruiting
  • Gastric Cancer
  • SOX plus Paclitaxel(albumin-bound) followed by PD-1 antibody
  • Beijing, Beijing, China
    National Cancer Center/National Clinical Research Center for Can
Sep 12, 2022

Metastatic Gastric Cancer, PD-L1 Gene Amplification, FGFR2 Amplification Trial in New York (Nivolumab, Capecitabine,

Recruiting
  • Metastatic Gastric Cancer
  • +2 more
  • New York, New York
    Bureau for Cancer Research
May 10, 2023

NSCLC, Lung Diseases, Lung Tumors Trial in New Haven (Sitravatinib, Pembrolizumab)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • +8 more
  • New Haven, Connecticut
    Yale University
Oct 26, 2022

Gastric Cancer Trial in Shanghai (PLD, Oxaliplatin, Capecitabine)

Recruiting
  • Gastric Cancer
  • Shanghai, China
    Shanghai General Hospital
Sep 7, 2022

Solid Tumor, Adult Trial in Dallas (Isunakinra, PD-(L)1 Inhibitor)

Recruiting
  • Solid Tumor, Adult
  • Isunakinra
  • PD-(L)1 Inhibitor
  • Dallas, Texas
    Baylor Charles A. Simmons Cancer Center
Jul 20, 2021

Locally Advanced Angiosarcoma, Metastatic Angiosarcoma, Recurrent Angiosarcoma Trial in Houston (Quality-of-Life Assessment,

Recruiting
  • Locally Advanced Angiosarcoma
  • +2 more
  • Quality-of-Life Assessment
  • Sintilimab
  • Houston, Texas
    M D Anderson Cancer Center
Jul 31, 2022

Molecular PD-L1 PET/CT Imaging With 89Zr-atezolizumab in

Not yet recruiting
  • Metastatic Triple-Negative Breast Carcinoma
  • 89Zr-atezolizumab PET/CT
  • (no location specified)
Feb 22, 2023

Bladder Urothelial Carcinoma Trial in Nanjing (primary focal resection plus lymph node dissection, Tislelizumab, Gemcitabine

Recruiting
  • Bladder Urothelial Carcinoma
  • primary focal resection plus lymph node dissection
  • +2 more
  • Nanjing, Jiangsu, China
    The first affiliated hospital of Nanjing Medical University
Dec 7, 2022